Please login to the form below
Ocrevus
This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.
Roche’s Ocrevus boasts positive long-term data in MS
Following two years of using Ocrevus twice-yearly, 75% of relapsing-remitting multiple sclerosis (RRMS) patients had no evidence of disease activity. ... Ocrevus. Patients treated with Ocrevus also experienced an improvement in the majority of their
Latest news
-
Novartis wins FDA approval for relapsing MS drug Kesimpta
However, the drug will have fierce competition in the market, from rivals such as Roche’s Ocrevus (ocrelizumab) and Sanofi’s Aubagio, despite touting superior efficacy data over the latter. ... Both Kesimpta and Ocrevus selectively target the immune
-
Roche’s Soliris rival Enspryng bags FDA approval
The FDA approval of Enspryng, the first subcutaneous NMOSD treatment using novel recycling antibody technology, builds upon the work we’ve done in multiple sclerosis with Ocrevus to develop
-
Novartis builds its case for novel MS treatment ofatumumab
The MS market has long been dominated by Roche’s blockbuster drug Ocrevus (ocrelizumab), which is used in both relapsing forms of MS and primary progressive MS, although it is facing
-
Roche cites COVID-19 and biosimilars in Q2 decline
Although sales of Roche's newer drugs climbed by 37%, including haemophilia A treatment Hemlibra (emicizumab), multiple sclerosis therapy Ocrevus (ocrelizumab) and PD-1 inhibitor Tecentriq (atezolizumab), this was unable to ... In fact, uptake of both
-
J&J aims for US approval of MS drug ponesimod
A range of blockbuster therapies are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab).
More from news
Approximately 20 fully matching, plus 35 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- STEM Healthcare founder Rob Wood secures a 25% stake in performance-io
- Sinopharm’s COVID-19 vaccine scores approval in China
- Pfizer/BioNTech and Moderna increase COVID-19 vaccine supplies to the EU
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Gene Editing and Precision Medicine: The Future of Healthcare?
- CRM Design and Optimization for Life Science Organizations
- EMA begins rolling review process for Sputnik V COVID-19 vaccine
- MHRA to fast-track vaccines modified for new COVID-19 variants
- Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC
- Syneos Health Communications announces senior hires to Europe-based team
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
- A cultural shift in clinical research
- Research organisations across the board are experimenting with new technologies...
Quick links
Infographics
